首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1975281

全球DNA診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global DNA Diagnostics Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

DNA診斷市場預計將從2025年的188.1億美元成長到2034年的430.7億美元，2026年至2034年的複合年成長率為9.64%。

受精準醫療、疾病早期檢測和基因篩檢需求成長的推動，全球DNA診斷市場正經歷顯著擴張。遺傳性疾病、癌症和感染疾病的日益普及加速了分子診斷技術的應用。次世代定序（NGS）、基於PCR的檢測和基於CRISPR的診斷平台的進步提高了準確性和反應速度。人們對個人化治療和預防醫學的日益重視，進一步推動了已開發經濟體和新興經濟體的市場滲透率。

關鍵成長要素包括新生兒篩檢計畫的擴展、基因組研究投資的增加以及人工智慧（AI）在基因數據分析中的應用。製藥公司正在加強DNA診斷技術在伴隨診斷和標靶藥物開發的應用。此外，定序成本的降低和檢查室自動化技術的進步也提高了人們獲得先進基因檢測的機會。政府鼓勵基因組研究和人群健康篩檢計畫的政策正在創造有利的監管和資金籌措環境。

展望未來，腫瘤學、罕見疾病、生殖醫學和藥物遺傳學等領域的應用拓展預計將推動市場成長。家用基因檢測套組和直接面對消費者的檢測服務的普及可能會重塑整個產業格局。生物技術公司、研究機構和醫療服務提供者之間的策略合作將加速創新。隨著個人化醫療逐漸成為主流，DNA診斷預計仍將在全球預測性、預防性和精準醫療模式中發揮核心作用。

區域分析
北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 亞太其他地區
拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家

第10章競爭格局

最新趨勢
公司分類
供應鏈和銷售管道合作夥伴（根據現有資訊）
市場佔有率和市場定位分析（基於現有資訊）
供應商情況（基於現有資訊）
策略規劃

第11章：公司簡介

主要公司的市佔率分析
公司簡介
- Abbott Laboratories
- Agilent Technologies Inc
- Avalon GloboCare Corp
- Beckman Coulter Inc
- Bio-Rad Laboratories Inc
- Cepheid
- F. Hoffmann-La Roche Ltd
- GE HealthCare Technologies Inc
- Hologic Inc
- Illumina Inc
- Siemens Healthineers（Formerly Siemens Healthcare Private Limited）
- Thermo Fisher Scientific Inc

簡介目錄

Product Code: VMR112112254

The DNA Diagnostics Market size is expected to reach USD 43.07 Billion in 2034 from USD 18.81 Billion (2025) growing at a CAGR of 9.64% during 2026-2034.

The Global DNA Diagnostics Market is witnessing strong expansion driven by rising demand for precision medicine, early disease detection, and genetic screening. Increasing prevalence of hereditary disorders, cancer, and infectious diseases has accelerated the adoption of molecular diagnostic technologies. Advancements in next-generation sequencing (NGS), PCR-based testing, and CRISPR-based diagnostic platforms are improving accuracy and turnaround time. Growing awareness regarding personalized treatment approaches and preventive healthcare is further supporting market penetration across developed and emerging economies.

Key growth drivers include expanding newborn screening programs, increasing investments in genomics research, and the integration of artificial intelligence in genetic data interpretation. Pharmaceutical companies are increasingly leveraging DNA diagnostics for companion diagnostics and targeted drug development. Moreover, declining sequencing costs and improved laboratory automation are making advanced genetic tests more accessible. Government initiatives promoting genomic research and population health screening programs are creating favorable regulatory and funding environments.

Looking ahead, the market is expected to benefit from expanding applications in oncology, rare diseases, reproductive health, and pharmacogenomics. The shift toward home-based genetic testing kits and direct-to-consumer testing services is likely to reshape industry dynamics. Strategic collaborations between biotechnology firms, research institutes, and healthcare providers will accelerate innovation. As personalized healthcare becomes mainstream, DNA diagnostics will remain central to predictive, preventive, and precision medicine models worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Offering

Instruments
Reagents & Kits
Services & Software

By Technology

In Situ Hybridization
Mass Spectroscopy
Microarrays
Polymerase Chain Reaction (PCR)
Sequencing
Others

By Application

Cancer Genetics Tests
Infectious Diseases DNA Testing
Newborn Genetic Screening
Preimplantation & Reproductive Diagnosis
Non-Infectious Diseases DNA Testing
Hematology & Immunology/Identity Diagnostics & Forensics
Pharmacogenomics/Drug Metabolism
Prenatal DNA Carrier Screening
Others

By Specimen

Blood, Serum, and Plasma
Urine
Others

By End User

Diagnostic Laboratories
Hospitals & Clinics
Others

COMPANIES PROFILED

Abbott Laboratories, Agilent Technologies Inc, Avalon GloboCare Corp, Beckman Coulter Inc, BioRad Laboratories Inc, Cepheid, F HoffmannLa Roche Ltd, GE HealthCare Technologies Inc, Hologic Inc, Illumina Inc, Siemens Healthineers formerly Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc
We can customise the report as per your requirements.

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL DNA DIAGNOSTICS MARKET: BY OFFERING 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Offering
4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Reagents & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Services & Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DNA DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Technology
5.2. In Situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Mass Spectroscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Microarrays Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DNA DIAGNOSTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Application
6.2. Cancer Genetics Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Infectious Diseases DNA Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Newborn Genetic Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Preimplantation & Reproductive Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.6. Non-Infectious Diseases DNA Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.7. Hematology & Immunology/Identity Diagnostics & Forensics Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.8. Pharmacogenomics/Drug Metabolism Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.9. Prenatal DNA Carrier Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DNA DIAGNOSTICS MARKET: BY SPECIMEN 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast Specimen
7.2. Blood, Serum, and Plasma Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Urine Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DNA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

8.1. Market Analysis, Insights and Forecast End User
8.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL DNA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

9.1. Regional Outlook
9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.2.1 By Offering
- 9.2.2 By Technology
- 9.2.3 By Application
- 9.2.4 By Specimen
- 9.2.5 By End User
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.3.1 By Offering
- 9.3.2 By Technology
- 9.3.3 By Application
- 9.3.4 By Specimen
- 9.3.5 By End User
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.4.1 By Offering
- 9.4.2 By Technology
- 9.4.3 By Application
- 9.4.4 By Specimen
- 9.4.5 By End User
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.5.1 By Offering
- 9.5.2 By Technology
- 9.5.3 By Application
- 9.5.4 By Specimen
- 9.5.5 By End User
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 South East Asia
- 9.5.11 Rest of Latin America
9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.6.1 By Offering
- 9.6.2 By Technology
- 9.6.3 By Application
- 9.6.4 By Specimen
- 9.6.5 By End User
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

10.1. Recent Developments
10.2. Company Categorization
10.3. Supply Chain & Channel Partners (based on availability)
10.4. Market Share & Positioning Analysis (based on availability)
10.5. Vendor Landscape (based on availability)
10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL DNA DIAGNOSTICS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Company Profiles
- 11.2.1 Abbott Laboratories
- 11.2.2 Agilent Technologies Inc
- 11.2.3 Avalon GloboCare Corp
- 11.2.4 Beckman Coulter Inc
- 11.2.5 Bio-Rad Laboratories Inc
- 11.2.6 Cepheid
- 11.2.7 F. Hoffmann-La Roche Ltd
- 11.2.8 GE HealthCare Technologies Inc
- 11.2.9 Hologic Inc
- 11.2.10 Illumina Inc
- 11.2.11 Siemens Healthineers (Formerly Siemens Healthcare Private Limited)
- 11.2.12 Thermo Fisher Scientific Inc